Overview

Study Evaluating Pharmacovigilance Of Refacto AF

Status:
Completed
Trial end date:
2016-10-19
Target enrollment:
Participant gender:
Summary
The purpose of this observational study is to describe the incidence of adverse events among patients treated with Refacto AF in usual health care settings in Germany and Austria.
Details
Lead Sponsor:
Pfizer
Treatments:
Factor VIII